GenSight Biologics GSGTF Stock
GenSight Biologics Price Chart
GenSight Biologics GSGTF Financial and Trading Overview
| GenSight Biologics stock price | 0.24 USD |
| Previous Close | 0.8 USD |
| Open | 0.8 USD |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.8 - 0.8 USD |
| 52 Week Range | 0.8 - 4.75 USD |
| Volume | 1K USD |
| Avg. Volume | 0 USD |
| Market Cap | 36.95M USD |
| Beta (5Y Monthly) | 1.929885 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.38 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GSGTF Valuation Measures
| Enterprise Value | 44.2M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 7.594442 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 9.085 |
| Enterprise Value/EBITDA | -1.606 |
Trading Information
GenSight Biologics Stock Price History
| Beta (5Y Monthly) | 1.929885 |
| 52-Week Change | -34.73% |
| S&P500 52-Week Change | 19.24% |
| 52 Week High | 4.75 USD |
| 52 Week Low | 0.8 USD |
| 50-Day Moving Average | 3.1 USD |
| 200-Day Moving Average | 3.17 USD |
GSGTF Share Statistics
| Avg. Volume (3 month) | 0 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 46.18M |
| Float | 31.03M |
| Short Ratio | N/A |
| % Held by Insiders | 12.75% |
| % Held by Institutions | 35.49% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -572.14% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -42.12% |
| Return on Equity (ttm) | -7781.69% |
Income Statement
| Revenue (ttm) | 4.87M USD |
| Revenue Per Share (ttm) | 0.11 USD |
| Quarterly Revenue Growth (yoy) | -25.80% |
| Gross Profit (ttm) | 4.87M USD |
| EBITDA | -27525000 USD |
| Net Income Avi to Common (ttm) | -27625000 USD |
| Diluted EPS (ttm) | -0.73 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 10.61M USD |
| Total Cash Per Share (mrq) | 0.23 USD |
| Total Debt (mrq) | 17.86M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 1.567 |
| Book Value Per Share (mrq) | -0.331 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -33753000 USD |
| Levered Free Cash Flow (ttm) | -29489124 USD |
Profile of GenSight Biologics
| Country | United States |
| State | N/A |
| City | Paris |
| Address | 74, rue du Faubourg Saint-Antoine |
| ZIP | 75012 |
| Phone | 33 1 76 21 72 20 |
| Website | https://www.gensight-biologics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 45 |
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. The company was incorporated in 2012 and is headquartered in Paris, France.
Q&A For GenSight Biologics Stock
What is a current GSGTF stock price?
GenSight Biologics GSGTF stock price today per share is 0.24 USD.
How to purchase GenSight Biologics stock?
You can buy GSGTF shares on the OTC Markets EXMKT exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for GenSight Biologics?
The stock symbol or ticker of GenSight Biologics is GSGTF.
Which industry does the GenSight Biologics company belong to?
The GenSight Biologics industry is Biotechnology.
How many shares does GenSight Biologics have in circulation?
The max supply of GenSight Biologics shares is 130.11M.
What is GenSight Biologics Price to Earnings Ratio (PE Ratio)?
GenSight Biologics PE Ratio is now.
What was GenSight Biologics earnings per share over the trailing 12 months (TTM)?
GenSight Biologics EPS is -0.38 USD over the trailing 12 months.
Which sector does the GenSight Biologics company belong to?
The GenSight Biologics sector is Healthcare.